Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Osimertinib
Drug: Platinum
Drug: Etoposide

First Posted Date: 2018-06-26

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT03567642

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Daratumumab
Procedure: autologous hematopoietic cell transplantation

First Posted Date: 2018-06-14

Last Posted Date: 2024-03-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT03556332

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Wake Forest University (Data Collection Only), Winston-Salem, North Carolina, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 9 locations

Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

Recruiting

Conditions: Retinoblastoma
Pediatric Retinoblastoma

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT03546387

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Rucaparib
Radiation: Radiotherapy

First Posted Date: 2018-05-31

Last Posted Date: 2024-08-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 31

Registration Number: NCT03542175

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Phase 1

Active, not recruiting

Conditions: Myeloid Diseases

Interventions: Drug: Antithymocyte globulin (Rabbit)
Drug: fludarabine
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Rituxan
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2018-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03531736

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Small Cell Lung Carcinoma
Small-cell Lung Cancer

Interventions: Drug: Olaparib Pill 50 mg
Drug: Olaparib Pill 100 mg
Drug: Olaparib Pill 150 mg
Drug: Olaparib Pill 200 mg
Drug: Olaparib Pill 250 mg
Drug: Olaparib Pill 300 mg
Radiation: Radiotherapy

First Posted Date: 2018-05-22

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT03532880

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 6 locations

Geriatric Communication Skills Training Program for Oncology Clinicians

Not Applicable

Completed

Conditions: Lymphoma
Bone Marrow Transplant
GU Cancer
GI Cancer

Interventions: Behavioral: The Consultation and Relational Empathy (CARE) questionnaire
Behavioral: Self-Efficacy Assessment
Behavioral: Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Behavioral: UCLA Geriatrics Attitudes Scale
Behavioral: Course Evaluations
Behavioral: Patient activation measure (PAM) scale

First Posted Date: 2018-05-21

Last Posted Date: 2024-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 88

Registration Number: NCT03530969

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Cutaneous Squamous Cell Carcinoma
Head and Neck Cancer
Head and Neck Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Lenvatinib Pill
Drug: Cetuximab

First Posted Date: 2018-05-14

Last Posted Date: 2022-10-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03524326

Locations: 🇺🇸
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States

and more 4 locations

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Radiation: Hypofractionated ablative IMRT (HFA-IMRT)
Drug: capecitabine

First Posted Date: 2018-05-14

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT03523312

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Overnight Fasting After Completion of Therapy: The OnFACT Study

Not Applicable

Recruiting

Conditions: Childhood Cancer Survivors

Interventions: Other: usual care
Other: prolonged overnight fasting

First Posted Date: 2018-05-14

Last Posted Date: 2024-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT03523377

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Home Terms & Conditions Privacy Policy